Remarks
No documented evidence of efficacy
No documented evidence of efficacy
No evidence for efficacy as monotherapy or when combined with
glucocorticoids
Unless in the setting of rapidly progressive IgAN
No documented evidence of efficacy
No documented evidence of efficacy
Patients who wish to take fish oil should be advised of the dose and
formulation used in the published clinical trials that reported efficacy.
In a single RCT conducted in China, MMF with low-dose glucocorticoids
was noninferior to standard-dose glucocorticoids for the treatment of
incident IgAN presenting with proliferative histologic lesions (E or C
lesions with or without necrosis) on kidney biopsy and proteinuria
>1.0 g/d. There were significantly fewer glucocorticoid-related side
effects in the combination-therapy arm.
In the RCTs of MMF in non-Chinese patients there was no evidence for
efficacy of MMF monotherapy.
In a small, short-term RCT conducted in China, hydroxychloroquine
introduced to patients with proteinuria of 0.75–3.5 g/d despite optimized
ACEi/ARB reduced proteinuria by 48% versus 10% in the placebo group at
6 months.
Hydroxychloroquine has not been evaluated in non-Chinese patients.
